SLAMF7 and Miyoshi myopathy: In our study, rhSLAMF7 inhibited anti-SLAMF7-mediated ADCC activity on MM cells, indicating that a high concentration of sSLAMF7 in the BM microenvironment may suppress the effects of elotuzumab in MM patients.